Join our daily newsletter At The Bell to receive exclusive market insights
- Emyria (EMD) recruits the first patient in its phase 2B MDMA-assisted therapy trial for PTSD
- The trial will assess the efficacy, safety, and cost-effectiveness of MDMA as a potential treatment for PTSD at Emyria’s newly acquired treatment centre
- Emyria has secured its importation license from the Office of Drug Control (ODC) for its patient-ready MDMA to be used in the trial
- The company is bolstered by the recent rescheduling of MDMA and psilocybin as controlled medicines by the TGA from July 1, 2023
- EMD shares last traded at 14.5 cents
Emyria (EMD) has recruited the first patient in its phase 2B MDMA-assisted therapy trial for Post-Traumatic Stress Disorder (PTSD).
The trial is designed to assess the efficacy, safety, and cost-effectiveness of MDMA-assisted therapy as a potential treatment for PTSD at Emyria’s newly acquired psychological trauma treatment centre, The Pax Centre.
The company hopes the data gathered will form the beginning of a comprehensive national patient data registry to support safety monitoring, research, and payer engagement, as well as assist authorised prescriber applications for Emyria’s psychiatrists.
Emyria has secured its importation license from the Office of Drug Control (ODC) for its patient-ready MDMA to be used in the trial, and additional patients have been identified from Pax’s existing database.
Furthermore, Emyria and The Pax Centre are now developing care models for psilocybin-assisted therapy to assess treatment-resistant depression, as well as additional clinical trial protocols to broaden and expand the knowledge of how these new interventions work for additional indications.
The recent rescheduling of MDMA and psilocybin as controlled medicines by the Australian Therapeutic Goods Administration from July 1, 2023, offers exciting opportunities for healthcare in broadening the clinical alternative treatments.
EMD shares last traded at 14.5 cents.
